Kappos, Ludwig
Traboulsee, Anthony
Li, David K. B.
Bar-Or, Amit
Barkhof, Frederik
Montalban, Xavier
Leppert, David
Baldinotti, Anna
Schneble, Hans-Martin
Koendgen, Harold
Sauter, Annette
Wang, Qing
Hauser, Stephen L.
Funding for this research was provided by:
F. Hoffmann-La Roche
University of Basel
Article History
Received: 12 May 2023
Revised: 10 August 2023
Accepted: 14 August 2023
First Online: 31 October 2023
Declarations
:
: L. Kappos’ institution (University Hospital Basel) has received the following exclusively for research support: steering committee, advisory board, and consulting fees (Actelion, Bayer HealthCare, Biogen, BMS, Genzyme, Janssen, Merck, Novartis, Roche, Sanofi, Santhera, and TG Therapeutics); speaker fees (Bayer HealthCare, Biogen, Merck, Novartis, Roche, and Sanofi); support of educational activities (Allergan, Bayer HealthCare, Biogen, CSL Behring, Desitin, Genzyme, Merck, Novartis, Roche, Pfizer, Sanofi, Shire, and Teva Pharmaceuticals); license fees for Neurostatus products; and grants (Bayer HealthCare, Biogen, European Union, InnoSwiss, Merck, Novartis, Roche, Swiss MS Society, and Swiss National Research Foundation). A. Traboulsee has received research support from Sanofi-Genzyme and Roche; has received consulting fees from Sanofi-Genzyme, Roche, Novartis, Biogen, and EMD Serono; and has received honoraria for his involvement in speaker bureau activities for Sanofi-Genzyme, Biogen, and Roche. D.K.B. Li has received research funding from the Canadian Institute of Health Research and Multiple Sclerosis Society of Canada. He is Emeritus Director of the UBC MS/MRI Research Group, which has been contracted to perform central analysis of MRI scans for therapeutic trials with Roche and Sanofi-Genzyme. The UBC MS/MRI Research Group has also received grant support for investigator-initiated studies from Genzyme, Novartis, and Roche. He has been a consultant to Vertex Pharmaceuticals and Genzyme, and has served on the Scientific Advisory Board for Celgene and the PML-MS Steering Committee for Biogen. He has given lectures supported by non-restricted education grants from Academy of Health Care Learning, Biogen, Consortium of MS Centers, and Sanofi-Genzyme. A. Bar-Or has received consulting fees from Actelion, Accure, Atara Biotherapeutics, Biogen Idec., BMS/Celgene/Receptos, Genentech/Roche, Gossamer, MedImmune, Merck/EMD Serono, Novartis, Sanofi-Genzyme, and GlaxoSmithKline. He has carried out contracted research for Genentech and Biogen; and receives a salary from the Perelman School of Medicine, University of Pennsylvania. F. Barkhof reports other from <i>Neurology</i>, other from <i>Radiology</i>, other from <i>MSJ</i>, other from <i>Neuroradiology</i>, personal fees from Springer, personal fees and other from Bayer, personal fees from Biogen, grants from Roche, grants from Merck, grants from Biogen, personal fees from IXICO Ltd, other from GeNeuro, grants from IMI-EU, grants from GE Healthcare, grants from UK MS Society, grants from Dutch Foundation MS Research, grants from NWO, grants from NIHR, and personal fees from Combinostics, outside the submitted work. X. Montalban has received speaking honoraria and travel expenses for participation in scientific meetings, has been a steering committee member of clinical trials, or participated in advisory boards of clinical trials in the past years with AbbVie, Actelion, Alexion, Biogen, Bristol Myers Squibb/Celgene, EMD Serono, Genzyme, F. Hoffmann-La Roche Ltd, Immunic, Janssen Pharmaceuticals, MedDay, Merck, Mylan, Nervgen, Novartis, Sandoz, Sanofi-Genzyme, Teva Pharmaceuticals, TG Therapeutics, Excemed, MSIF, and NMSS. D. Leppert is a Chief Medical Officer of GeNeuro, Geneva, Switzerland; and has been an employee of and stockholder in F. Hoffmann-La Roche Ltd and Novartis AG. A. Baldinotti is an employee of F. Hoffmann-La Roche Ltd. H-M Schneble is an employee of and shareholder in F. Hoffmann-La Roche Ltd. H. Koendgen was an employee of and shareholder in F. Hoffmann-La Roche Ltd during completion of the work related to this manuscript. He is currently an employee of UCB Farchim SA, Bulle, Switzerland. A. Sauter was an employee of F. Hoffmann-La Roche Ltd during completion of this work; she is currently an employee of Janssen Pharmaceuticals. Q. Wang is an employee of F. Hoffmann-La Roche Ltd. S.L. Hauser serves on the Board of Directors for Neurona and on scientific advisory boards for Annexon, Alector, and Accure; and has received travel reimbursement and writing assistance from F. Hoffmann-La Roche Ltd and Novartis for CD20-related meetings and presentations.
: The relevant institutional review boards/ethics committees approved the protocols (ClinicalTrials.gov identifier number NCT00676715). All patients (or witnesses, if both patient and legally acceptable representative were unable to read) provided written informed consent.